Cabaletta Bio reported the exercise of warrants issued during its June 2025 underwritten public offering. From issuance through June 30, 2026, 5,275,100 warrants were exercised for approximately $13.2 million in gross proceeds. Between July 1, 2026 and the expiration date of September 12, 2026, an additional 46,011,900 warrants were exercised, generating approximately $115.0 million in gross proceeds. The total aggregate gross proceeds from all warrant exercises amount to approximately $128.2 million. Cabaletta Bio operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.

Cabaletta Bio, Inc. reported financial results for the second quarter ended June 30, 2026, showing a net loss of $51.0 million and R&D expenses of $44.4 million. The company holds approximately $225.1 million in cash, providing runway into mid-2027. Clinically, registrational RESET-Myositis data is on track for mid-2027 to support a BLA submission in the second half of 2027, while a new registrational study for SSc-associated ILD is expected to initiate in the fourth quarter of 2026. The company also expanded its manufacturing supply chain by partnering with ElevateBio as an additional CDMO and announced a 10-year agreement with Cellares for automated production. Cabaletta Bio operates in the biotechnology industry, developing curative targeted cell therapies for autoimmune diseases.

At its Annual Meeting of Stockholders on June 9, 2026, Cabaletta Bio, Inc. stockholders approved an amendment to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 600,000,000. The company filed a Certificate of Amendment with the State of Delaware on the same day. Cabaletta Bio, Inc. is a biotechnology company focused on cell and gene therapy.